Agenus Posts 48% Q2 Revenue Miss
(NASDAQ:AGEN), a clinical-stage biotechnology company focused on developing cancer immunotherapies, reported its second quarter 2025 earnings on August 11, 2025. The company's revenue (GAAP) totaled $25.7 million, well below analyst expectations of $49.71 million (GAAP) -- a miss of 48.3% (GAAP). The results reflect a significant shortfall on both top and bottom lines on a GAAP basis. Despite the financial underperformance, the company made material clinical and regulatory advances, most notably securing U.S. Food and Drug Administration agreement to initiate a streamlined Phase 3 trial for its key cancer therapy. Overall, the period featured operational improvements but underwhelming financials.
Source: Analyst estimates for the quarter provided by FactSet.
specializes in immuno-oncology, developing therapies that help the body's immune system fight cancer. Its main product candidates are part of a new class of medicines called checkpoint inhibitors, which are designed to disrupt cancer cells' ability to avoid immune detection.
Source Fool.com
